GZP’s core professional team averages more than 25 years of hands-on experience each across their respective disciplines — Regulatory Affairs, CMC/Product Quality, Preclinical/Nonclinical Development, Clinical Development, Medical Writing, and Electronic Submissions. With careers shaped by work under FDA, EMA, TGA, and other global regulatory authorities, our consultants have contributed directly to the development of some of today’s most transformative therapies, including novel monoclonal antibody constructs, somatic cell therapies, oncolytic virus therapies, and treatment vaccines. Spanning more than 18 therapeutic areas, GZP brings the focused, practical expertise clients need to confidently navigate biologic/biotechnology, pharmaceutical, medical device, and combination product development.

Founded in 1999, Ground Zero Pharmaceuticals, Inc. (GZP), and its wholly owned Australian subsidiary, Ground Zero Pharmaceuticals Pty Ltd., was established as an integrated consulting firm with a singular focus: helping clients advance their products efficiently, strategically, and successfully through the global regulatory landscape.

With offices in Irvine, California and Melbourne, VIC, Australia, and associates throughout the US, Australia, Canada, Germany, and Sweden, GZP provides clients with expert strategic and tactical guidance — with an eye toward the global regulatory gold standard set by the US FDA — to help develop their products, build their firms, prioritize their pipelines, obtain marketing approvals, and pursue post-marketing activities.

GZP focuses on tailoring each client program to provide the best strategic advice for efficient medical product progress toward the ultimate milestone — product approval. Rather than simply quoting FDA guidelines, GZP gathers a comprehensive understanding of all available client data, integrates this with deep global expertise, and provides specific, actionable recommendations based on the complete picture.

The regulatory environment is always evolving, new technologies are continuously emerging, and the FDA is constantly refining what it requires of Sponsors. Each key regulatory question may have multiple valid answers — GZP understands that individual data points, studies, and supporting documentation, channeled in a logical and targeted manner, can ultimately lead to a “yes” from the Agency.

GZP takes an integrated approach to product development — in both its people and its philosophy. Team members with backgrounds spanning multiple disciplines, combined with efficient cross-functional collaboration, provide clients with a uniquely cohesive approach to executing their programs.

GZP recognizes that each technical discipline — regulatory strategy, preclinical/nonclinical, clinical, and chemistry, manufacturing and controls — directly influences the others at every phase of development. Strategic regulatory considerations are woven throughout the fabric of every program to best facilitate progress toward marketing approval. By integrating all relevant disciplines toward shared problem-solving, GZP has consistently found that FDA reviewers and sponsors alike can negotiate solutions more quickly and flexibly than through the traditional compartmentalized approach.